Pharmacy services billed under the medical benefit represent an expanding opportunity for pharmacists to deliver and be reimbursed for clinical care beyond traditional dispensing. These services often include administration of medications such as long-acting injectables and specialty drugs, point-of-care testing paired with immediate treatment, and ongoing patient management activities like remote monitoring or follow-up care. Billing under the medical benefit typically requires alignment with medical coding, documentation, and payer policies, but it enables pharmacies to participate more directly in value-based care models, improve patient access to timely interventions, and integrate more fully into the broader healthcare delivery system.
The March 2026 poll results indicate that respondents see the greatest opportunity for expansion in both long-acting injectable medications and point-of-care testing with treatment, each receiving 40% of the vote. This suggests strong confidence in pharmacists’ ability to deliver high-impact, accessible clinical interventions that address immediate and ongoing patient needs. Remote patient monitoring and clinical follow-up services also garnered some support at 20%, reflecting growing interest in longitudinal care models. Notably, services such as chronic care management, specialty drug administration, and diabetic supplies/DME received no votes, which may indicate perceived barriers to implementation, reimbursement complexity, or lower awareness of opportunity compared to more established or rapidly evolving service lines.
Beyond vaccines, which pharmacy service billed under the medical benefit do you believe provides the greatest opportunity for expansion?
Long-acting injectable medications (e.g., antipsychotics, biologics): 40%
Point-of-care testing with treatment (e.g., flu, strep, COVID test-and-treat) 40%
Chronic care management / medication therapy management (MTM): 0%
Specialty drug administration: 0%
Remote patient monitoring or clinical follow-up services: 20%
Diabetic supplies and durable medical equipment (DME): 0%